GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the highly-regarded journal Nature Medicine has published the first case report of partial recovery of visual function in a blind patient with late-stage retinitis pigmentosa (RP). The subject is a participant in the ongoing PIONEER Phase I/II clinical trial of GenSight Biologics’ GS030 optogenetic therapy. Published in the May issue under the title “Partial recovery of visual function in a blind patient after optogenetic therapy”, the paper* is the first peer-reviewed documentation of visual recovery after a blind patient was treated with optogenetic therapy.